查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1945841

注意力不足過動症市場－全球產業規模、佔有率、趨勢、機會及預測（依藥物類型、通路、地區及競爭格局分類，2021-2031年）

Attention Deficit Hyperactivity Disorder, Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球注意力不足過動症(ADHD) 市場預計將從 2025 年的 178.2 億美元成長到 2031 年的 232.5 億美元，複合年成長率為 4.53%。

該市場涵蓋各類藥物製劑，包括興奮劑和非興奮劑類藥物，以及旨在緩解注意力不足、過動和衝動等症狀的治療設備。大眾對神經發育障礙的認知不斷提高，以及診斷通訊協定的改進（能夠更好地識別成人人群中的此類疾病），是推動市場成長的主要因素。此外，醫療基礎設施的改善和精神健康服務保險覆蓋範圍的擴大，也持續推動全球對這些治療性介入的需求。

市場概覽
預測期 2027-2031
市場規模：2025年 178.2億美元
市場規模：2031年 232.5億美元
複合年成長率：2026-2031年 4.53%
成長最快的細分市場 網路藥房
最大的市場 北美洲

然而，由於長期存在的供應鏈中斷和生產瓶頸，市場擴張面臨許多重大障礙。這些物流限制經常導致藥品短缺，阻礙病患治療的連續性。根據美國國家社區藥劑師協會 (NCPA) 的一項調查，到 2024 年，94% 的獨立藥局業主表示將面臨 Adderall 或其學名藥短缺的問題。這種產品供應的不穩定性嚴重威脅著產業的信譽，並限制了市場穩定成長的潛力。

市場促進因素

兒童和成人族群中注意力不足過動症(ADHD) 盛行率和診斷率的上升是全球 ADHD 市場的主要促進因素。雖然 ADHD 傳統上主要在兒童中被發現，但隨著臨床認知的提高以及圍繞神經發育障礙的污名化現象的消除，成人 ADHD 的診斷數量激增，尤其是在以前診斷不足的女性群體中。這種人口結構的變化顯著擴大了患者群體，並推動了對治療性介入的持續需求。根據美國精神醫學會 (APA) 2025 年 1 月發布的數據，2020 年至 2023 年間，成人 ADHD 新診斷病例增加了 15%。此外，美國緝毒局 (DEA) 2024 年 11 月的一份報告預測，2023 年美國興奮劑處方量將達到 8,080 萬張，這反映了市場需求的巨大規模。

同時，遠距精神病學和數位健康解決方案的普及徹底改變了患者獲得過動症治療的途徑，成為市場成長的關鍵驅動力。遠端系統管理平台消除了地理和物流障礙，實現了持續監測和藥物管理，這對患者堅持治療方案至關重要。這種數位轉型在應對新患者激增的問題上極為有效，這些患者可能面臨長時間的專家面診預約等待。根據美國疾病管制與預防中心 (CDC) 2024 年 10 月發布的報告，約 46% 的過動症成年患者表示曾使用遠端醫療服務，證實了虛擬醫療模式在當前醫療保健環境中的重要作用。

市場挑戰

長期存在的供應鏈中斷和生產瓶頸是目前限制全球注意力不足過動症（ADHD）藥物市場成長的主要因素。這些物流方面的不穩定性導致製藥公司無法滿足不斷成長的診斷率所帶來的需求。當生產無法跟上消費者需求時，由此造成的藥品短缺會導致即時的收入損失，並阻礙患者堅持處方治療方案。產品供應的不確定性削弱了現有治療方法的商業性穩定性，造成市場波動，並阻礙了產品的持續推廣。

這些藥品短缺對製藥業的影響顯而易見，並直接阻礙了市場的穩定發展。根據美國衛生系統藥劑師協會統計，2024年第一季出現了創紀錄的323種藥品短缺，其中大部分是用於治療注意力不足過動症（ADHD）的興奮劑。這些大範圍的供應鏈中斷迫使醫療機構發行，並推遲治療的開始時間。這種不確定的環境限制了市場持續擴張的潛力，並對相關人員的長期財務前景產生了負面影響。

市場趨勢

作為戰略研發轉型的一部分，新型非興奮劑藥物正在重塑市場格局。研發重點在於開發能夠避免二類管制興奮劑濫用風險和監管複雜性的製劑。製藥公司正加大對具有獨特作用機制的非管制藥物的投資，以確保在興奮劑短缺期間治療的連續性。新核准的非興奮劑藥物迅速佔領市場，滿足了尋求可靠長期治療方案且不受生產配額限制的患者的需求，這就是該轉型的有力佐證。 Supernus Pharmaceuticals 於 2025 年 2 月宣布，其非興奮劑藥物 Qelbree 的 2024 年全年淨銷售額將成長 72%，達到 2.413 億美元，這進一步印證了人們對這類替代治療方法的日益青睞。

同時，人工智慧 (AI) 和機器學習在診斷流程中的應用，正在克服以往主觀症狀報告的局限性，並建立新的臨床客觀性標準。透過分析複雜的行為數據和運動模式，這些計算工具能夠為臨床醫生提供精準的生物標記物，從而減少診斷的不確定性，尤其是在症狀往往較為隱匿的成年人群體中。這項技術進步顯著提高了初步評估的準確性，並簡化了採取適當干預措施的路徑。 Qbtech 公司於 2025 年 8 月發布的一項研究表明，在英國(NHS) 中應用混合機器學習演算法，在識別成人注意力不足過動症 (ADHD) 方面實現了 93.61% 的診斷準確率，凸顯了人工智慧驅動的精準醫療的巨大潛力。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球注意力不足過動症（ADHD）市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依藥物類型（興奮劑、非興奮劑）
    • 按分銷管道（零售藥局、醫院藥局、網路藥局）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美注意力不足過動症（ADHD）市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲注意力不足過動症(ADHD) 市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區注意力不足過動症（ADHD）市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲注意力不足過動症（ADHD）市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲注意力不足過動症（ADHD）市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球注意力不足過動症（ADHD）市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Supernus Pharmaceuticals, Inc.
  • Pfizer Inc
  • Novartis AG
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Hisamitsu Pharmaceutical Co., Inc.
  • Chongqing Fujin Biology Medical Company
  • Purdue Pharma LP
  • Mallinckrodt Pharmaceuticals

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 19777

The Global Attention Deficit Hyperactivity Disorder (ADHD) Market is projected to expand from USD 17.82 Billion in 2025 to USD 23.25 Billion by 2031, registering a CAGR of 4.53%. This market encompasses pharmaceutical formulations, including both stimulants and non-stimulants, alongside therapeutic devices designed to mitigate symptoms such as inattention, hyperactivity, and impulsivity. Growth is propelled by increasing public acknowledgment of neurodevelopmental conditions and refined diagnostic protocols that better identify adult populations. Furthermore, improved healthcare infrastructure and expanded insurance coverage for mental health services continue to actively support the global demand for these therapeutic interventions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 17.82 Billion
Market Size 2031USD 23.25 Billion
CAGR 2026-20314.53%
Fastest Growing SegmentOnline Pharmacies
Largest MarketNorth America

Nevertheless, market expansion faces substantial obstacles due to chronic supply chain disruptions and manufacturing bottlenecks. These logistical constraints frequently result in medication scarcities that hamper consistent patient access to treatment. According to the National Community Pharmacists Association, 94 percent of independent pharmacy owners reported experiencing shortages of Adderall or its generic equivalents in 2024. Such instability in product availability poses a critical challenge to industry reliability and limits the potential for steady market growth.

Market Driver

The rising prevalence and diagnosis rates among pediatric and adult populations represent a primary catalyst for the Global Attention Deficit Hyperactivity Disorder (ADHD) Market. While ADHD has historically been identified primarily in children, increased clinical understanding and the destigmatization of neurodevelopmental disorders have led to a surge in adult identifications, particularly among women who were previously underdiagnosed. This demographic shift is significantly expanding the patient pool and driving sustained demand for therapeutic interventions. According to the American Psychiatric Association in January 2025, new ADHD diagnoses among adults increased by 15 percent between 2020 and 2023, while the U.S. Drug Enforcement Administration noted in November 2024 that the projected number of stimulant prescriptions dispensed in the United States reached 80.8 million in 2023, reflecting the substantial scale of market demand.

Concurrently, the proliferation of telepsychiatry and digital health solutions is revolutionizing patient access to ADHD care, acting as a critical driver for market growth. Remote management platforms have dismantled geographical and logistical barriers, allowing for more consistent monitoring and medication management, which is essential for adherence to treatment regimens. This digital shift has been instrumental in accommodating the influx of new patients who might otherwise face long wait times for in-person specialists. According to the Centers for Disease Control and Prevention in October 2024, nearly 46 percent of adults with ADHD reported having utilized telehealth services for their condition, underscoring the pivotal role of virtual care models in the current healthcare landscape.

Market Challenge

Chronic supply chain disruptions and manufacturing bottlenecks currently act as a primary restraint on the growth of the Global Attention Deficit Hyperactivity Disorder Market. These logistical inconsistencies result in the inability of pharmaceutical producers to meet the rising demand driven by increased diagnosis rates. When production fails to align with consumption requirements, the resulting medication scarcity leads to immediate revenue losses and disrupts patient adherence to prescribed therapeutic regimens. This unreliability in product availability compromises the commercial stability of established treatments and creates market volatility that discourages consistent product utilization.

The impact of these shortages is quantitatively significant within the pharmaceutical sector and directly impedes steady market progress. According to the American Society of Health-System Pharmacists, the industry faced an all-time high of 323 active drug shortages during the first quarter of 2024, a figure that heavily comprised central nervous system stimulants used for ADHD management. Such extensive gaps in the supply chain force healthcare providers to ration care or delay treatment initiation. This environment of uncertainty limits the potential for sustained market expansion and negatively affects the long-term financial outlook for stakeholders.

Market Trends

A strategic R&D shift towards novel non-stimulant pharmacotherapies is reshaping the market, prioritizing formulations that circumvent the abuse risks and regulatory complexities associated with Schedule II stimulants. Pharmaceutical developers are increasingly investing in non-controlled substances with unique mechanisms of action to ensure continuity of care during periods of stimulant scarcity. This pivot is evidenced by the rapid commercial uptake of recently approved non-stimulant options among patients seeking reliable, long-term management solutions that remain unaffected by production quotas. According to Supernus Pharmaceuticals in February 2025, the full-year 2024 net sales for its non-stimulant treatment Qelbree surged by 72 percent to reach $241.3 million, underscoring the growing preference for these alternative therapeutic modalities.

Concurrently, the integration of artificial intelligence and machine learning in diagnostic workflows is establishing new standards for clinical objectivity, addressing the historical limitations of subjective symptom reporting. By analyzing complex behavioral data and motor activity patterns, these computational tools provide clinicians with precise biomarkers that reduce diagnostic ambiguity, particularly in adult populations where symptom presentation is often subtle. This technological evolution is significantly improving the accuracy of initial assessments and streamlining the pathway to appropriate intervention. According to Qbtech in August 2025, a study implementing hybrid machine learning algorithms within the National Health Service framework demonstrated a diagnostic accuracy of 93.61 percent for identifying adult ADHD, highlighting the transformative potential of AI-driven precision medicine.

Key Market Players

  • Supernus Pharmaceuticals, Inc.
  • Pfizer Inc
  • Novartis AG
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Hisamitsu Pharmaceutical Co., Inc.
  • Chongqing Fujin Biology Medical Company
  • Purdue Pharma LP
  • Mallinckrodt Pharmaceuticals

Report Scope

In this report, the Global Attention Deficit Hyperactivity Disorder (ADHD) Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Attention Deficit Hyperactivity Disorder (ADHD) Market, By Drug Type

  • Stimulant
  • Non-stimulant

Attention Deficit Hyperactivity Disorder (ADHD) Market, By Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • online Pharmacies

Attention Deficit Hyperactivity Disorder (ADHD) Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Attention Deficit Hyperactivity Disorder (ADHD) Market.

Available Customizations:

Global Attention Deficit Hyperactivity Disorder (ADHD) Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (Stimulant, Non-stimulant)
    • 5.2.2. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, online Pharmacies)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Distribution Channel

7. Europe Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Distribution Channel

10. South America Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Attention Deficit Hyperactivity Disorder (ADHD) Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Attention Deficit Hyperactivity Disorder (ADHD) Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Supernus Pharmaceuticals, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Pfizer Inc
  • 15.3. Novartis AG
  • 15.4. Eli Lilly and Company
  • 15.5. GlaxoSmithKline PLC
  • 15.6. Johnson & Johnson
  • 15.7. Hisamitsu Pharmaceutical Co., Inc.
  • 15.8. Chongqing Fujin Biology Medical Company
  • 15.9. Purdue Pharma LP
  • 15.10. Mallinckrodt Pharmaceuticals

16. Strategic Recommendations

17. About Us & Disclaimer